Biostatistics Program

Task Force on Disparities in Urologic Health


Ruth Etzioni

Dr. Etzioni’s work focuses on statistical and computer modeling for policy development, with a focus on prostate cancer research. Dr. Etzioni’s models of disease have been used to estimate the lifetime probabilities of prostate cancer and its outcomes, study the extent of overdiagnosis associated with prostate cancer screening, and quantify the roles of screening and changes in receipt of initial therapies in explaining population mortality declines. 

Petros Grivas

Dr. Petros Grivas is a board-certified medical oncologist with expertise and experience in treating genitourinary (GU) cancers. He is the new Clinical Director of the Genitourinary Cancers Program at University of Washington and Associate Professor in the Dept of Medicine, Division of Oncology. He was recruited from the Cleveland Clinic, where he led the bladder/urothelial cancer program and helped pioneer a project to support education and informed-decision making about prostate cancer screening in an underserved area. 

Daniel Lin

Dr. Daniel W. Lin is the chief of urologic oncology at the University of Washington Department of Urology and a urologist specializing in genitourinary oncologic surgery.

Bruce Montgomery

Bruce Montgomery, M.D.  is professor of Oncology at the University of Washington, Fred Hutchinson Cancer Research Center and VA Puget Sound in Seattle, Washington.  His research focuses on carrying out clinical research studies of mechanisms of resistance and sensitivity of tumors through molecular characterization of normal and somatic tissue from patients with prostate and bladder cancers.   

Janet Stanford

Dr. Stanford's research interests focus on hormonal, environmental, lifestyle and genetic factors that may alter cancer risk, tumor progression, and disease outcomes such as recurrence-free and cancer-specific survival. The role of underlying genetic susceptibility is a major focus of my research, which has involved studies of both common and rare genetic variants in the general at-risk population and in high-risk families with a pattern of hereditary prostate cancer. 

Jonathan Wright

Dr. Wright is a urologic oncologist at the University of Washington, Seattle Cancer Care Alliance and Seattle-Puget Sound Veterans Affairs Hospital.  He is also an Associate Investigator at the Fred Hutchinson Cancer Research Center and has a Masters Degree in Epidemiology.